Celon Pharma (WAR:CLN) Construction In Progress: zł65.3 Mil (As of Mar. 2026)


WAR:CLN Celon Pharma SA WAR:CLN
57 GF Score
Price zł19.86
GF Value zł22.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Construction In Progress?

Celon Pharma WAR:CLN -0.20% 57 Construction In Progress is zł65.3 Mil as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 57/100 and a GF Value™ of zł22.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Celon Pharma's quarterly construction in progress declined from Sep. 2025 (zł38.0 Mil) to Dec. 2025 (zł0.0 Mil) but then increased from Dec. 2025 (zł0.0 Mil) to Mar. 2026 (zł65.3 Mil).

Celon Pharma's annual construction in progress declined from Dec. 2023 (zł80.0 Mil) to Dec. 2024 (zł0.0 Mil) but then stayed the same from Dec. 2024 (zł0.0 Mil) to Dec. 2025 (zł0.0 Mil).

Celon Pharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Construction In Progress Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.48 74.30 79.95 0.00 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.11 37.77 38.04 0.00 65.32
WAR:CLN
57GF Score
Celon Pharma SA WAR:CLN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of zł65.3 Mil mean?
Celon Pharma (WAR:CLN) has a Construction In Progress of zł65.3 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Construction In Progress too high?
Celon Pharma's current Construction In Progress is zł65.3 Mil. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Construction In Progress compare to ZTS and UTHR?
Celon Pharma's Construction In Progress of zł65.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Celon Pharma and its competitors. Celon Pharma's current Construction In Progress is zł65.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.61, compared to a current price of zł19.86 — trading 12.2% below its estimated fair value. The current Construction In Progress is zł65.3 Mil. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Construction In Progress is zł65.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.86 is trading 12.2% below its estimated GF Value™ of zł22.61. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Construction In Progress: zł65.3 Mil
  • GF Value™: zł22.61 vs. price of zł19.86 (12.2% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score

Get the complete analysis for WAR:CLN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.86
Price
zł22.61
GF Value